These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 8629034

  • 1. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ, Thomssen C, duBois A, Lisboa BW, Untch M, Kuhnle H, Konecny G, Janicke F, Meerpohl HG, Lindner C, Hecker D, Diergarten K.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ, Thomssen C, du Bois A, Untch M, Lisboa B, Köhler G, Diergarten K.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [Abstract] [Full Text] [Related]

  • 3. Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Lück HJ, Thomssen C, du Bois A, Lisboa BW, Untch M, Kühnle H, Jänicke F, Meerpohl HG, Lindner C, Konecny G, Hecker D, Diergarten K.
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S13-6. PubMed ID: 9071334
    [Abstract] [Full Text] [Related]

  • 4. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF, Michelotti A, Baldini E, Salvadori B, Gennari A, Da Prato M, Tibaldi C, Salzano E, Gentile A.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G, Spielmann M, Dieras V, Kayitalire L, Pouillart P, Guastalla JP, Soler-Michel P, Graffand N, Garet F, Dumortier A, Pellae-Cosset B, Chazard M.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [Abstract] [Full Text] [Related]

  • 6. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 7. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF, Michelotti A, Baldini E, Tibaldi C, DaPrato M, Salvadori B, Giannessi PG, Gentile A, Biadi O, Mariani M.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [Abstract] [Full Text] [Related]

  • 8. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G, Spielmann M, Dieras V, Tubiana-Hulin M, Bonneterre J, Pouillart P, Kayitalire L, Guastalla JP, Graffand N, Garet F, Dumortier A, Pellae-Cosset B.
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
    Lück HJ, Du Bois A, Thomssen C, Lisboa B, Untch M, Köhler G, Hecker D.
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
    [Abstract] [Full Text] [Related]

  • 11. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [Abstract] [Full Text] [Related]

  • 12. A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Tienghi A, Ravaioli A, Casadei Giunchi D, Gentile A, Salzano E.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):19-23. PubMed ID: 8629031
    [Abstract] [Full Text] [Related]

  • 13. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
    Tolcher AW, Gelmon KA.
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):28-32. PubMed ID: 7638639
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [Abstract] [Full Text] [Related]

  • 16. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U, Harstrick A, Wilke H, Seeber S.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL, Johnson DH.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [Abstract] [Full Text] [Related]

  • 20. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F, Duhem C, Kleiber K, Dicato M.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.